Cargando…
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the p...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111512/ https://www.ncbi.nlm.nih.gov/pubmed/27872732 http://dx.doi.org/10.4084/MJHID.2016.052 |
_version_ | 1782467879359217664 |
---|---|
author | Del Principe, Maria Ilaria Buccisano, Francesco Maurillo, Luca Sconocchia, Giuseppe Cefalo, Mariagiovanna Consalvo, Maria Irno Sarlo, Chiara Conti, Consuelo De Santis, Giovanna De Bellis, Eleonora Di Veroli, Ambra Palomba, Patrizia Attrotto, Cristina Zizzari, Annagiulia Paterno, Giovangiacinto Voso, Maria Teresa Del Poeta, Giovanni Lo-Coco, Francesco Arcese, William Amadori, Sergio Venditti, Adriano |
author_facet | Del Principe, Maria Ilaria Buccisano, Francesco Maurillo, Luca Sconocchia, Giuseppe Cefalo, Mariagiovanna Consalvo, Maria Irno Sarlo, Chiara Conti, Consuelo De Santis, Giovanna De Bellis, Eleonora Di Veroli, Ambra Palomba, Patrizia Attrotto, Cristina Zizzari, Annagiulia Paterno, Giovangiacinto Voso, Maria Teresa Del Poeta, Giovanni Lo-Coco, Francesco Arcese, William Amadori, Sergio Venditti, Adriano |
author_sort | Del Principe, Maria Ilaria |
collection | PubMed |
description | Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the patients’ risk allocation process, distinguishing more adequately those who are likely to recur from those who are not. In this view, there is now evidence that the submicroscopic amounts of leukemic cells (called minimal residual disease, MRD), measured during the course of treatment, indicate the quality of response to therapy. Therefore, MRD might serve as an independent, additional biomarker to help to identify patients at higher risk of relapse. Detection of MRD requires the use of highly sensitive ancillary techniques, such as polymerase chain reaction (PCR) and multiparametric flow cytometry(MPFC). In the present manuscript, we will review the current approaches to investigate MRD and its clinical applications in AML management. |
format | Online Article Text |
id | pubmed-5111512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Università Cattolica del Sacro Cuore |
record_format | MEDLINE/PubMed |
spelling | pubmed-51115122016-11-21 Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications Del Principe, Maria Ilaria Buccisano, Francesco Maurillo, Luca Sconocchia, Giuseppe Cefalo, Mariagiovanna Consalvo, Maria Irno Sarlo, Chiara Conti, Consuelo De Santis, Giovanna De Bellis, Eleonora Di Veroli, Ambra Palomba, Patrizia Attrotto, Cristina Zizzari, Annagiulia Paterno, Giovangiacinto Voso, Maria Teresa Del Poeta, Giovanni Lo-Coco, Francesco Arcese, William Amadori, Sergio Venditti, Adriano Mediterr J Hematol Infect Dis Review Article Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the patients’ risk allocation process, distinguishing more adequately those who are likely to recur from those who are not. In this view, there is now evidence that the submicroscopic amounts of leukemic cells (called minimal residual disease, MRD), measured during the course of treatment, indicate the quality of response to therapy. Therefore, MRD might serve as an independent, additional biomarker to help to identify patients at higher risk of relapse. Detection of MRD requires the use of highly sensitive ancillary techniques, such as polymerase chain reaction (PCR) and multiparametric flow cytometry(MPFC). In the present manuscript, we will review the current approaches to investigate MRD and its clinical applications in AML management. Università Cattolica del Sacro Cuore 2016-10-20 /pmc/articles/PMC5111512/ /pubmed/27872732 http://dx.doi.org/10.4084/MJHID.2016.052 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Del Principe, Maria Ilaria Buccisano, Francesco Maurillo, Luca Sconocchia, Giuseppe Cefalo, Mariagiovanna Consalvo, Maria Irno Sarlo, Chiara Conti, Consuelo De Santis, Giovanna De Bellis, Eleonora Di Veroli, Ambra Palomba, Patrizia Attrotto, Cristina Zizzari, Annagiulia Paterno, Giovangiacinto Voso, Maria Teresa Del Poeta, Giovanni Lo-Coco, Francesco Arcese, William Amadori, Sergio Venditti, Adriano Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications |
title | Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications |
title_full | Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications |
title_fullStr | Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications |
title_full_unstemmed | Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications |
title_short | Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications |
title_sort | minimal residual disease in acute myeloid leukemia of adults: determination, prognostic impact and clinical applications |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111512/ https://www.ncbi.nlm.nih.gov/pubmed/27872732 http://dx.doi.org/10.4084/MJHID.2016.052 |
work_keys_str_mv | AT delprincipemariailaria minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT buccisanofrancesco minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT maurilloluca minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT sconocchiagiuseppe minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT cefalomariagiovanna minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT consalvomariairno minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT sarlochiara minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT conticonsuelo minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT desantisgiovanna minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT debelliseleonora minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT diveroliambra minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT palombapatrizia minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT attrottocristina minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT zizzariannagiulia minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT paternogiovangiacinto minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT vosomariateresa minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT delpoetagiovanni minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT lococofrancesco minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT arcesewilliam minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT amadorisergio minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications AT vendittiadriano minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications |